Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T22:10:40.909Z.
Calculation as of: 2026-10-06T22:10:40.909Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7e7d16b5ba5167ceff619aa020f317ca223699ac3cb4068fa61dc11e0d5c4076
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$4.40M
EV/EBITDA Ratio
N/A
TTM Avg
72.60x
3Y Avg
72.60x
5Y Avg
72.60x
Market Cap
$4.21M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| 20/20 Biolabs Inc. (AIDX) | $4.32M | N/A | N/A | N/A | N/A |
| CollPlant Biotechnologies Ltd. (CLGN)vs › | $4.40M | N/A | 72.60x | 72.60x | 72.60x |
| Processa Pharmaceuticals, Inc. (PCSA)vs › | $4.21M | N/A | N/A | N/A | N/A |
| GRI Bio, Inc. (GRI)vs › | $4.15M | N/A | N/A | N/A | N/A |
| PharmaCyte Biotech, Inc. (PMCB)vs › | $4.53M | N/A | N/A | N/A | N/A |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.55M | N/A | N/A | N/A | N/A |
| CalciMedica, Inc. (CALC)vs › | $4.69M | N/A | N/A | N/A | N/A |
| Imunon, Inc. (IMNN)vs › | $4.71M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.93M | N/A | N/A | N/A | N/A |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.72M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
